Sarepta’s Duchenne gene therapy wins OK; FDA spurns NASH drug; Eli Lilly buys DICE for $2.4B; The new antitrust landscape; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The End­points 11 is back. This year, John Car­roll will be team­ing up with Drew Arm­strong, Ryan Cross, An­drew Dunn and Kyle LaHu­cik to se­lect and pro­file the 2023 edi­tion of our an­nu­al re­port on some of the most promis­ing pri­vate biotechs out there. Nom­i­nate your fa­vorite biotech here.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN